Labcorp will present abstracts in the areas of immunology, cellular biology, genomics and liquid biopsy at the Annual Meeting of the American Association for Cancer Research® (AACR®) in San Diego (April 5-10, 2024). The depth and breadth of Labcorp's oncology research solidifies the company's commitment to delivering guideline-based, biomarker-driven testing solutions, strengthening existing evidence of clinical utility and supporting the pharmaceutical industry from discovery to companion diagnostics development through commercialization to facilitate patient access to novel targeted therapies. Of the 21 abstracts to be presented at the AACR Meeting, 13 were internal studies by Labcorp researchers and eight were conducted in collaboration with research partners from premiere academic institutions and medical centers.
Laboratory Corporation of America Holdings
Equities
LH
US50540R4092
Healthcare Facilities & Services
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
211.2 USD | +0.39% | +4.81% | -7.08% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.08% | 17.73B | |
+18.41% | 83.07B | |
-29.08% | 70.89B | |
+3.59% | 28.32B | |
+2.07% | 17.43B | |
+0.93% | 15.64B | |
+6.78% | 13.46B | |
+8.40% | 12.82B | |
+68.45% | 12.69B | |
+70.12% | 12.32B |
- Stock Market
- Equities
- LH Stock
- News Laboratory Corporation of America Holdings
- Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research